AlphaCrest Capital Management LLC Takes $1.09 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

AlphaCrest Capital Management LLC acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 37,624 shares of the medical equipment provider’s stock, valued at approximately $1,087,000.

A number of other hedge funds have also made changes to their positions in LNTH. Maryland State Retirement & Pension System increased its stake in shares of Lantheus by 1.5% in the fourth quarter. Maryland State Retirement & Pension System now owns 26,986 shares of the medical equipment provider’s stock worth $780,000 after purchasing an additional 386 shares in the last quarter. O Shaughnessy Asset Management LLC boosted its position in shares of Lantheus by 20.7% during the third quarter. O Shaughnessy Asset Management LLC now owns 5,056 shares of the medical equipment provider’s stock worth $130,000 after acquiring an additional 866 shares during the last quarter. Diversified Trust Co boosted its position in shares of Lantheus by 7.3% during the fourth quarter. Diversified Trust Co now owns 14,011 shares of the medical equipment provider’s stock worth $405,000 after acquiring an additional 955 shares during the last quarter. Advisor Group Holdings Inc. grew its stake in Lantheus by 6.2% during the fourth quarter. Advisor Group Holdings Inc. now owns 17,576 shares of the medical equipment provider’s stock valued at $507,000 after acquiring an additional 1,031 shares in the last quarter. Finally, First Manhattan Co. lifted its stake in Lantheus by 39.5% in the 3rd quarter. First Manhattan Co. now owns 4,324 shares of the medical equipment provider’s stock worth $111,000 after purchasing an additional 1,224 shares in the last quarter. 97.14% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have recently weighed in on LNTH. SVB Leerink raised their price objective on Lantheus from $34.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, February 24th. Truist Financial raised their price objective on Lantheus from $77.00 to $94.00 in a research report on Monday, May 2nd. StockNews.com began coverage on Lantheus in a research report on Thursday, March 31st. They set a “hold” rating for the company. Zacks Investment Research upgraded Lantheus from a “sell” rating to a “hold” rating and set a $74.00 price objective for the company in a research report on Tuesday, May 3rd. Finally, B. Riley started coverage on Lantheus in a research report on Monday, May 9th. They set a “buy” rating and a $91.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Lantheus currently has an average rating of “Buy” and a consensus target price of $83.50.

In other news, CEO Mary Anne Heino sold 43,909 shares of the firm’s stock in a transaction that occurred on Monday, February 28th. The shares were sold at an average price of $46.50, for a total transaction of $2,041,768.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gerard Ber sold 1,277 shares of the firm’s stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $58.19, for a total transaction of $74,308.63. Following the transaction, the director now directly owns 32,703 shares in the company, valued at $1,902,987.57. The disclosure for this sale can be found here. In the last three months, insiders sold 125,171 shares of company stock valued at $6,422,140. 1.60% of the stock is owned by insiders.

Shares of NASDAQ:LNTH opened at $64.00 on Friday. The company has a current ratio of 1.83, a quick ratio of 1.64 and a debt-to-equity ratio of 0.31. Lantheus Holdings, Inc. has a 12 month low of $19.30 and a 12 month high of $69.74. The company has a 50-day moving average price of $57.58 and a 200 day moving average price of $38.81. The company has a market cap of $4.39 billion, a price-to-earnings ratio of -112.28, a PEG ratio of 0.62 and a beta of 0.76.

Lantheus (NASDAQ:LNTH – Get Rating) last announced its quarterly earnings results on Friday, April 29th. The medical equipment provider reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.51. The firm had revenue of $208.90 million during the quarter, compared to the consensus estimate of $165.30 million. Lantheus had a negative net margin of 6.89% and a positive return on equity of 19.83%. The firm’s revenue for the quarter was up 125.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.05 EPS. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 2.78 EPS for the current year.

Lantheus Company Profile (Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Featured Stories